Skip to main content
We report a case series of patients with coronavirus disease 2019 (COVID-19) with pulmonary embolism (PE) in our institution. Lille University Hospital is the tertiary care center for the North of France, the second greatest French region in population density (189 people per 1 km2), also considered a metabolic area with high number of overweight patients. The study was approved by the institutional data protection authority of Lille University Hospital.
Among the 107 first consecutive patients with confirmed COVID-19 admitted to the intensive care unit (ICU) for pneumonia from February 27 to March 31, we noticed an unexpectedly high number of PEs during their stay in the ICU: 22 (20.6%) at the time of analysis (April 9), within a median time from ICU admission of 6 days (range, 1–18 days). To determine whether this represents an increase in the expected incidence of PE over a similar time interval, we analyzed the files of 196 patients hospitalized in our ICU during the same time interval in 2019. Despite a similar severity score on admittance to the ICU, the frequency of PE in our COVID-19 series was twice as high as the frequency we found in this control period (20.6% versus 6.1%; absolute increased risk, 14.4% [95% CI, 6.1–22.8]). It was also twice as high as the 7.5% frequency of PE in the 40 patients with influenza admitted to the ICU between January 1 and December 30, 2019 (3 PEs; absolute increased risk, 13.1% [95% CI, 1.9–24.3]). A qualitative description of the main characteristics of the patients with PE in the different periods is given in the Table.
Table. Number of CTPAs Performed for Suspicion of PE and Number and Main Characteristics of PE Events in the ICU From the COVID-19 Pandemic Period Compared With the Same Period in 2019 and With Patients With Influenza in 2019
 Study Period
February 27–March 31, 2019 (All ICU Patients*, n=196)January 1–December 31, 2019 (Patients With Influenza in the ICU [PCR+], n=40)February 27–March 31, 2020 (Patients With COVID-19 in the ICU [PCR+], n=107)
Chest CT scans, n (%)50 (25.5)20 (50.0)36 (33.6)
CTPAs, n (%)30 (15.3)17 (42.5)34 (31.8)
CTPAs performed for a PE diagnosis, n (%)20 (10.2)8 (20.0)34 (31.8)
PE cases, n (%)12 (6.1)3 (7.5)22 (20.6)
 Bilateral8 (66.6)08 (40.0)§
 Proximal2 (16.6)02 (10.0)§
 Segmental6 (50.0)011 (55.0)§
ARDS, n (%)14 (7.1)15 (37.5)67 (62.6)
Intubation, n (%)84 (42.9)17 (42.5)67 (62.6)
Doppler ultrasound, n (%)12 (6.1)2 (5.0)8 (7.5)
 DVT, n (%)9 (4.6)1 (2.5)5 (4.7)
Patients with PE
 Age, median (range), y66 (30–72)71 (57–72)57 (29–80)
 Men, n (%)8 (66.7)2 (66.7)13 (59.1)
 Body mass index, median (range), kg/m229 (18–42)26 (16–52)30 (22–53)
 SOFA score at admission, median (range)8 (1–16)2 (1–9)4 (0–14)
 SAPS II at admission, median (range)53 (23–69)41 (34–65)40 (18–78)
 ARDS, n (%)5 (41.7)2 (66.7)17 (77.3)
 Intubation, n (%)8 (66.7)3 (100.0)17 (77.3)
 DVT associated with PE, n (%)7 (58.3)1 (33.4)3 (13.6)
The SAPS II score provides an estimate of the risk of death without having to specify a primary diagnosis. It includes physiological variables, type of admission and underlying disease variables. Point score between 0 and 163 predicts mortality between 0% and 100%.; SOFA is a mortality prediction score that is based on the degree of dysfunction of six organ systems. The score is calculated on admission and every 24 hours, ranging from 0 (normal) to 4 (high degree of dysfunction/failure) for each organ failure. ARDS indicates acute respiratory distress syndrome; BMI, body mass index; COVID-19, coronavirus disease 2019; CT, computed tomography; CTPA, computed tomography pulmonary angiography; DVT, deep venous thrombosis ICU, intensive care unit; PCR, polymerase chain reaction; PE, pulmonary embolism; SAPS II, Simplified Acute Physiology Score; and SOFA, Sequential Organ Failure Assessment.
*
Reasons for hospitalization in this group were acute respiratory failure (34%), sepsis/septic shock (19%), strokes and other neurological disorders (10%), nonseptic shock (6%), cardiac arrest (6%), intoxication (6%), metabolism disorders (4%), postoperative conditions (5%), microangiopathies (1.5%), acute kidney injury (1.5%), and others (7%: pancreatitis, self-hanging injury, severe trauma, gas embolism).
Corresponding to an absolute increase of 14.4% (95% CI, 6.1–22.8%) vs control group of patients admitted to the ICU from February 27 to March 31, 2019, and 13.1% (95% CI, 1.9–24.3) vs control group of patients with influenza admitted to the ICU from January 1 to December 31, 2019.
The 3 PEs identified in patients with influenza were unilateral and subsegmental.
§
Two missing values.
One missing value.
Taking into account the ICU duration at time of analysis, we estimated the cumulative incidence of PE using the Kalbfleisch and Prentice method by taking into account death (n=15) and discharged alive (n=48) as competing events. The 22 patients still hospitalized in the ICU without PE at the time of analysis (median ICU length of stay, 15 days; range, 10–30 days) were treated as censored observations. At day 15 of ICU admission, the cumulative incidence of PE in patients with COVID-19 in the ICU was estimated to be 20.4% (95% CI, 13.1–28.7). In terms of the main data at ICU admission (using the univariable Fine and Gray model to estimate subhazard ratios of PE), D-dimers (estimate subhazard ratio per log-SD increase, 1.81 [95% CI, 1.03–3.16]), plasma factor VIII activity (estimate subhazard ratio per log-SD increase, 1.73 [95% CI, 1.10–2.72]), and von Willebrand factor antigen (estimate subhazard ratio per log-SD increase, 1.69 [95% CI, 1.12–2.56]) values seem to be associated with a greater PE risk.
At the time of PE diagnosis, 20 of 22 patients were receiving prophylactic antithrombotic treatment (unfractionated heparin or low-molecular-weight heparin) according to the current guidelines in critically ill patients.1,2 One patient with a history of deep venous thrombosis was receiving fluindione with an international normalized ratio in the therapeutic range, and 1 patient was receiving therapeutic unfractionated heparin because of atrial fibrillation. The criteria for deciding to perform computed tomography pulmonary angiography (CTPA) were suspicion of PE on admission and acute degradation of hemodynamic or respiratory status. All CTPAs were performed with multibar computed tomography with no difference in the injection protocol regardless of whether the CTPA was performed for PE diagnosis. The number of CTPAs was higher in patients with COVID-19 than in patients hospitalized in the ICU during the same time period in 2019. This historical control group reflects the global practice in our ICU. Because only 34% of patients from this group have respiratory failure requiring CTPA (Table), a potential bias of an increased detection of PE in patients with COVID-19 could have been generated. That is why we compared patients with COVID-19 and patients with influenza admitted to the ICU for respiratory failure in 2019. Even if the number of CTPAs performed in patients with influenza was higher than in patients with COVID-19, fewer PEs were identified, reinforcing the increased risk of PE in patients with COVID-19. The low number of associated deep venous thromboses in patients with COVID-19 may suggest that they have pulmonary thrombosis rather than embolism.
PE frequency has not yet been reported in the different series of patients with COVID-19. All our patients received thromboprophylaxis according to the current recommendations for critically ill medical patients. However, we suspect that the high obesity prevalence in our patient group contributes to the increased PE frequency.3 Because of the lack of specific studies in this population, the recommendations do not mention adaptation of the prophylaxis regimen in overweight patients or a need to monitor anti–factor Xa concentrations. Heparin could have benefic effects in COVID-19 through different mechanisms. However, the effective dose and monitoring are discussed, in particular in very high-risk patients and those with high body mass index.4 Indeed, during the H1N1 flu pandemic, some centers reported an increased thrombotic risk in patients with severe acute respiratory distress syndrome and suggested the use of higher doses of heparin.5
In conclusion, there is an urgent need for replication on a much larger scale of our data on PE frequency in COVID-19 infection in patients in the ICU. Failure to identify and accurately manage this risk could worsen the prognosis of patients with COVID-19.

Acknowledgments

The authors wish to thank the Lille COVID Research Network (LICORNE) and the i-site for their support during the COVID-19 pandemic.

Supplemental Material

File (10.1161.circulationaha.120.047430_supplemental_file.pdf)
File (cotr_covid.mp3)
File (cotr_covid.pdf)

Appendix

For the Lille ICU Haemostasis COVID-19 Group

Nicolas Cousin, Arthur Durand, Ahmed El Kalioubie, Raphaël Favory, Patrick Girardie, Marion Houard, Emmanuelle Jaillette, Mercé Jourdain, Geoffrey Ledoux, Daniel Mathieu, Anne-Sophie Moreau, Christopher Niles, Saad Nseir, Thierry Onimus, Sébastien Préau, Laurent Robriquet, Anahita Rouzé, Arthur Simonnet, Sophie Six, Aurélia Toussaint, Annabelle Dupont, Anne Bauters, Christophe Zawadzki, Camille Paris, Nathalie Trillot, Bénédicte Wibaut, Audrey Hochart, Catherine Marichez, Vincent Dalibard, Sandrine Vanderziepe, Laureline Bourgeois, Anaïs Gaul, Aurélie Jospin, Nataliia Stepina, Bénédicte Pradines, Antoine Tournoys, Thierry Brousseau, Martine Rémy, Antoine Hutt

References

1.
Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl):e195S–e226S. doi: 10.1378/chest.11-2296
2.
Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, Rezende SM, Zakai NA, Bauer KA, Dentali F, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2:3198–3225. doi: 10.1182/bloodadvances.2018022954
3.
Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, Labreuche J, Mathieu D, Pattou F, Jourdain M, Lille Intensive Care COVID-19 and Obesity Study Group. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation [published online April 9, 2020]. Obesity (Silver Spring). doi: 10.1002/oby.22831
4.
Thachil J. The versatile heparin in COVID-19 [published online April 2, 2020]. J Thromb Haemost. doi: 10.1111/jth.14821
5.
Obi AT, Tignanelli CJ, Jacobs BN, Arya S, Park PK, Wakefield TW, Henke PK, Napolitano LM. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. J Vasc Surg Venous Lymphat Disord. 2019;7:317–324. doi: 10.1016/j.jvsv.2018.08.010

eLetters(0)

eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.

Information & Authors

Information

Published In

Go to Circulation
Circulation
Pages: 184 - 186
PubMed: 32330083

Versions

You are viewing the most recent version of this article.

History

Published online: 24 April 2020
Published in print: 14 July 2020

Permissions

Request permissions for this article.

Keywords

  1. body mass index
  2. COVID-19
  3. D-dimer
  4. factor VIII
  5. pulmonary embolism
  6. thrombosis
  7. von Willebrand factor

Subjects

Authors

Affiliations

Julien Poissy, MD, PhD [email protected]
Université de Lille, Inserm U1285, CHU Lille, Pôle de réanimation, CNRS, UMR 8576–UGSF–Unité de Glycobiologie Structurale et Fonctionnelle, France (J.P.).
Julien Goutay, MD
CHU Lille, Pôle de réanimation, France (J.G., M.C., E.P., T.D.).
Morgan Caplan, MD
CHU Lille, Pôle de réanimation, France (J.G., M.C., E.P., T.D.).
Erika Parmentier, MD
CHU Lille, Pôle de réanimation, France (J.G., M.C., E.P., T.D.).
Thibault Duburcq, MD
CHU Lille, Pôle de réanimation, France (J.G., M.C., E.P., T.D.).
Fanny Lassalle, PharmD
Université de Lille, Inserm, CHU Lille, Department of Hematology and Transfusion, Pôle de Biologie Pathologie Génétique, Institut Pasteur de Lille, UMR1011-EGID, France (F.L., E.J., A.R., S.S.).
Emmanuelle Jeanpierre, PharmD
Université de Lille, Inserm, CHU Lille, Department of Hematology and Transfusion, Pôle de Biologie Pathologie Génétique, Institut Pasteur de Lille, UMR1011-EGID, France (F.L., E.J., A.R., S.S.).
Antoine Rauch, MD, PhD
Université de Lille, Inserm, CHU Lille, Department of Hematology and Transfusion, Pôle de Biologie Pathologie Génétique, Institut Pasteur de Lille, UMR1011-EGID, France (F.L., E.J., A.R., S.S.).
Julien Labreuche, BST
Université de Lille, CHU Lille, ULR 2694–METRICS: Évaluation des technologies de santé et des pratiques médicales, France (J.L.).
Université de Lille, Inserm, CHU Lille, Department of Hematology and Transfusion, Pôle de Biologie Pathologie Génétique, Institut Pasteur de Lille, UMR1011-EGID, France (F.L., E.J., A.R., S.S.).
Lille ICU Haemostasis COVID-19 Group

Notes

*
A complete list of members of the Lille ICU Haemostasis COVID-19 Group is provided in the Appendix.
Data, analytical methods, and study materials are available to other researchers on request by email.
Julien Poissy, MD, PhD, Pôle de Réanimation, Hôpital Roger Salengro, Rue Emile Laine, CHU Lille, 59037 Lille Cedex, France; Email [email protected]
Sophie Susen, MD, PhD, Institut Cœur-Poumon (Heart and Lung Institute), Hemostasis Department, Bd du Pr Leclercq, CHU Lille, 59037 Lille Cedex, France. Email [email protected]

Disclosures

None.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

  1. Low Molecular Weight Heparin Dosing in Relation to Postoperative Bleeding After Tracheotomy in Patients Infected With SARS ‐ CoV ‐2—A Descriptive Study , Laryngoscope Investigative Otolaryngology, 10, 2, (2025).https://doi.org/10.1002/lio2.70122
    Crossref
  2. Description of the clinical and radiological characteristics of pulmonary embolism in COVID-19 vs non–COVID-19 patients: a multicentric cross-sectional study over a 24-month perspective, Journal of Thrombosis and Haemostasis, 23, 4, (1332-1339), (2025).https://doi.org/10.1016/j.jtha.2024.12.037
    Crossref
  3. Global hotspot and trend of extracorporeal membrane oxygenation for pulmonary embolism, Frontiers in Medicine, 12, (2025).https://doi.org/10.3389/fmed.2025.1531716
    Crossref
  4. Pulmonary embolism detected by CT pulmonary angiography in hospitalized COVID-19 patients, Pulmonology, 27, 4, (348-351), (2025).https://doi.org/10.1016/j.pulmoe.2021.03.007
    Crossref
  5. Pulmonary artery thrombosis in COVID-19 patients, Pulmonology, 27, 3, (261-263), (2025).https://doi.org/10.1016/j.pulmoe.2020.07.013
    Crossref
  6. Impact of SARS-CoV-2 infection therapies on the risk of venous thromboembolism and cardiovascular events from the SEMI-COVID-19 Registry, Scientific Reports, 15, 1, (2025).https://doi.org/10.1038/s41598-025-90278-8
    Crossref
  7. SARS-CoV-2 vaccination reduces the risk of thrombotic complications in severe COVID-19, Medicina Intensiva (English Edition), (502167), (2025).https://doi.org/10.1016/j.medine.2025.502167
    Crossref
  8. The prevalence of thromboembolic events among COVID-19 patients admitted to a single centre intensive care unit (ICU): an epidemiological study from a Malaysian population, Journal of Pharmaceutical Policy and Practice, 18, 1, (2025).https://doi.org/10.1080/20523211.2024.2449044
    Crossref
  9. The clinical features and outcomes of diabetes patients infected with COVID-19: a systematic review and meta-analysis comprising 192,693 patients, Frontiers in Medicine, 12, (2025).https://doi.org/10.3389/fmed.2025.1523139
    Crossref
  10. The impact of COVID-19 on patients with heart failure and valvular disease, COVID-19 and the Cardiovascular System, (233-255), (2025).https://doi.org/10.1016/B978-0-443-14001-3.00013-3
    Crossref
  11. See more
Loading...

View Options

View options

PDF and All Supplements

Download PDF and All Supplements

PDF/EPUB

View PDF/EPUB
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to access the full text.

Purchase access to this journal for 24 hours

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

Figures

Tables

Media

Share

Share

Share article link

Share

Comment Response